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Abstract
Background: Liver fibrosis is characterized by excessive synthesis of extracellular matrix proteins, which prevails over their
enzymatic degradation, primarily by matrix metalloproteinases (MMPs). The effect of pharmacological MMP inhibition on
fibrogenesis, however, is largely unexplored. Inflammation is considered a prerequisite and important co-contributor to
fibrosis and is, in part, mediated by tumor necrosis factor (TNF)-a-converting enzyme (TACE). We hypothesized that
treatment with a broad-spectrum MMP and TACE-inhibitor (Marimastat) would ameliorate injury and inflammation, leading
to decreased fibrogenesis during repeated hepatotoxin-induced liver injury.
Methodology/Principal Findings: Liver fibrosis was induced in mice by repeated carbon tetrachloride (CCl4) administration,
during which the mice received either Marimastat or vehicle twice daily. A single dose of CCl4 was administered to
investigate acute liver injury in mice pretreated with Marimastat, mice deficient in Mmp9, or mice deficient in both TNF-a
receptors. Liver injury was quantified by alanine aminotransferase (ALT) levels and confirmed by histology. Hepatic collagen
was determined as hydroxyproline, and expression of fibrogenesis and fibrolysis-related transcripts was determined by
quantitative reverse-transcription polymerase chain reaction. Marimastat-treated animals demonstrated significantly
attenuated liver injury and inflammation but a 25% increase in collagen deposition. Transcripts related to fibrogenesis were
significantly less upregulated compared to vehicle-treated animals, while MMP expression and activity analysis revealed
efficient pharmacologic MMP-inhibition and decreased fibrolysis following Marimastat treatment. Marimastat pre-treatment
significantly attenuated liver injury following acute CCl4-administration, whereas Mmp9 deficient animals demonstrated no
protection. Mice deficient in both TNF-a receptors exhibited an 80% reduction of serum ALT, confirming the
hepatoprotective effects of Marimastat via the TNF-signaling pathway.
Conclusions/Significance: Inhibition of MMP and TACE activity with Marimastat during chronic CCl4 administration
counterbalanced any beneficial anti-inflammatory effect, resulting in a positive balance of collagen deposition. Since
effective inhibition of MMPs accelerates fibrosis progression, MMP inhibitors should be used with caution in patients with
chronic liver diseases.
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Introduction
Hepatic fibrosis represents the wound healing response to
chronic insult and is the final common pathway for most chronic
liver diseases, regardless of their mechanism [1–3]. Progressive
fibrosis ultimately leads to increased mortality and morbidity from
portal hypertension, end-stage liver failure and ultimately
cirrhosis, and is associated with an increased risk of hepatic
malignancies [4]. Currently, the only definitive treatment for
advanced fibrosis and cirrhosis is liver transplantation; however,
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the demand for organ grafts outweighs their availability [5],
stressing the need for effective antifibrotic approaches [6,7].
Hepatocellular injury usually leads to inflammation and
activation of the innate immune system, leading to release of
growth factors, cytokines and small molecular mediators that can
stimulate extracellular matrix (ECM) synthesis by activation of
quiescent hepatic stellate cells and fibroblasts/myofibroblasts
(collectively named HSCs) [1,2]. Upon fibrogenic activation,
HSCs as well as inflammatory cells release and respond to the
cytokine transforming growth factor (TGF)-b [8]. TGF-b strongly
upregulates production and deposition of the major ECM
constituents, while it downregulates fibrolytic matrix metallopro-
teinases (MMPs) [8,9]. In the presence of chronic hepatic injury,
an imbalance between fibrogenesis and fibrolysis may lead to
excess ECM deposition and scar formation.
Cell surface-bound and soluble MMPs along with their
endogenous tissue inhibitors (TIMPs) constitute an important
system for regulating ECM turnover; however, MMPs also
regulate inflammatory processes [10]. Chronic inflammation is
an important driver in fibrogenesis, serving both as a trigger and
perpetuator of fibrosis progression [11]. A critical mediator of the
inflammatory response is tumor necrosis factor (TNF)-a, which
exists in a biologically active, soluble form and as an inactive,
membrane-anchored precursor [12]. Cleavage of the TNF-a
proform into its soluble form is mediated by TNF-a-converting
enzyme (TACE, also known as ADAM17 and CD156b), which
belongs to the disintegrin and metalloproteinase (ADAM) family of
zinc-metalloproteinases [13,14]. Mice deficient in TIMP3, the
endogenous physiological inhibitor of TACE [15], demonstrate
elevated levels of TNF-a and develop severe inflammation of the
liver, presumably due to depressed TACE activity [16]. In
contrast, pharmacologic TACE-inhibition abrogates the inflam-
matory response and has been demonstrated to have therapeutic
potential in a variety of pathological conditions [17,18]. Many
TACE-inhibitors, however, are relatively non-specific and also
inhibit various MMPs.
MMPs are widely believed to be important players in fibrosis
due to their collagen-cleaving activity [19–21]. Identification of
novel MMP substrates, however, revealed their involvement in
highly complex processes such as the regulation of cell behavior,
cell-cell communication, and tumor progression [22,23]. Hence,
these insights indicate that MMPs have a much more complex
function in fibrosis than merely ECM degradation. Effects of
MMP-inhibition on fibrogenesis, however, remain to be estab-
lished. We hypothesized that treatment with a broad-spectrum
MMP and TACE-inhibitor would ameliorate both injury and
inflammation, resulting in decreased fibrosis formation in a murine
model of repeated carbon tetrachloride (CCl4) administration.
Results
Chronic broad-spectrum MMP-inhibition dramatically
reduces histological liver injury in mice subjected to
chronic CCL4-intoxication
Chronic CCl4-administration resulted in liver enlargement and
fibrosis (Figure 1A). Liver sections of vehicle treated controls
exhibited areas of necrosis, steatosis, and inflammatory lympho-
cytic infiltrates –hallmarks of severe chronic hepatic injury
(Figure 1B). Liver sections from Marimastat treated animals,
however, showed a significant reduction in steatosis (Figure 1C),
inflammation (Figure 1D) and necrosis (Figure 1E), suggesting
attenuation of hepatic injury and inflammation, despite a loss of
body weight (Figure 1F).
Marimastat treatment markedly blunts the increase of
serum ALT and levels of TNF-a receptor II in CCl4-induced
chronic hepatic injury
Marimastat treatment resulted in a 1.4-fold reduction of
alkaline phosphatase levels (P#0.05, Figure 2A) and a 14-fold
decrease in serum ALT levels (P#0.05, Figure 2B), indicating
markedly decreased hepatic injury following repeated CCl4-
administration. Serum levels of soluble TNF-a receptor II (p75)
were 1.2-fold decreased in Marimastat treated animals
(P#0.05), likely reflecting pharmacologic inhibition of TACE
and an ameliorated inflammatory response (Figure 2C)
[22,24]. Serum IL-6 levels were increased 2.9-fold (P#0.05),
suggesting hepatoprotection and stimulated liver regeneration
(Figure 2D) [25].
Marimastat treatment leads to downregulation of major
pro-fibrogenic genes
Hepatic expression of procollagen a1(I), b6 Integrin, TGF-b1,
TGF-b2, alpha-smooth muscle actin (a-SMA) and TIMP-1
mRNA were strongly upregulated following repeated CCl4-
administration (Figure 3). Concomitant treatment with Marima-
stat, however, significantly decreased hepatic transcript levels of
procollagen a1(I) (Figure 3A), TGF-b2 (Figure 3D), a-SMA
(Figure 3E) and TIMP-1 (Figure 3F) compared to vehicle
treated controls, whereas b6 Integrin (Figure 3B) and TGF-b1
(Figure 3C) mRNA levels remained unchanged.
Marimastat does not diminish net collagen deposition
and fibrosis formation
Treatment of mice with Marimastat during chronic CCl4-
administration significantly increased the liver and the spleen (a
putative marker of portal hypertension) to body weight ratios,
compared to controls (Figure 4A, B). Liver sections of the vehicle
treated controls exhibited centrilobular fibrosis with areas of
necrosis, whereas liver sections from Marimastat treated animals
showed enhanced centrilobular collagen deposition indicating
increased fibrosis formation (Figure 4C). To directly quantify the
degree of fibrosis, we measured both relative (per g of liver) and
total (per whole liver) collagen content biochemically via hepatic
hydroxyproline determination. Marimastat treatment resulted in a
significant increase in relative and total collagen (hydroxyproline)
content (25% and 14%, respectively) compared to the controls
(Figures 4D, E). This was corroborated using morphometric
analysis of Sirius Red stained liver sections (Figure 4F),
demonstrating that the relative fibrotic area was significantly
increased in livers from mice treated with Marimastat, compared
to controls (4.2% versus 3.1%, respectively; P,0.05). These results
suggest dissociation between hepatic injury and inflammation on
the one hand, and the degree of fibrosis on the other hand, upon
pharmacological MMP inhibition.
Marimastat decreases hepatic stellate cell activation, but
increases recruitment of inflammatory cells
Immunohistochemical staining for a-SMA (Figure 5A), as a
marker for activated HSCs, was performed to confirm the
observed decrease in a-SMA mRNA (Figure 3E). a-SMA
positive cells were significantly increased following chronic CCl4-
administration; however, concomitant treatment with Marimastat
significantly decreased this number indicating decreased activa-
tion of a subset of activated HSCs (Figure 5A,B). This again
suggests that Marimastat treatment led to a decrease in fibrogenic
activity, which is in dissociation with the observed, net result of
increased fibrosis (Figure 4). To further explore this finding,
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immunohistochemical staining for T-cells and macrophages (i.e.,
Kupffer cells) was performed. Chronic administration of CCl4
induces an inflammatory response, elicited by accumulation of T-
cells and macrophages that remove injured hepatocytes and
stimulate fibroblast function [26]. Immunohistochemical staining
for CD3 (Figure 5C), as a marker for T-cells, revealed a 1.8-fold
increase in cell counts in Marimastat-treated animals that were
subjected to chronic CCl4-administration (Figure 5D). In
addition, cell counts from F4/80 positive cells, as a marker for
macrophages, revealed a 1.8-fold increase following treatment of
mice with Marimastat during chronic CCl4-administration
(Figure 5E,F).
Figure 1. Marimastat treatment reduced liver injury, necrosis, and inflammation following repeated carbon tetrachloride (CCl4)
administration. Chronic CCl4 administration resulted in liver enlargement and fibrosis (A). Hematoxylin and eosin staining of liver sections revealed
decreased steatosis and inflammation (yellow arrows), and no evidence of necrosis (black arrows) in the Marimastat treated mice (B). On liver sections
scored by a blinded pathologist and compared to vehicle treated controls, Marimastat treated animals showed a significantly lower steatosis score
(C), less inflammatory foci per 2006 field (D) and essentially no evidence of necrosis was observed (E); despite body weight loss (F). Oil, non-fibrotic
control group; CCl4, fibrotic mice; VEH, vehicle treated control group; MAR, Marimastat treated experimental group; ***, P,0.001 vs. vehicle alone.
Data are expressed as means 6 standard error. Original magnification: 2006.
doi:10.1371/journal.pone.0011256.g001
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Marimastat treatment downregulates MMP gene
expression and MMP-activities
To better understand the increased ECM deposition in animals
treated with Marimastat, we analyzed hepatic MMP expression
levels. In fibrotic animals, hepatic expression of MMP-2, MMP-3,
MMP-8, MMP-9 and MMP-13 mRNA were all significantly
upregulated, compared to non-fibrotic controls (Figure 6).
Marimastat treatment during chronic CCl4 administration,
however, did not affect hepatic transcript levels of MMP-2
(Figure 6A), or MMP-3 (Figure 6B), compared to vehicle treated
animals. Hepatic transcript levels of MMP-8 (Figure 6C) and
MMP-9 (Figure 6D) were 5.6-fold and 6.6-fold increased,
respectively, in livers from Marimastat treated animals, whereas
hepatic MMP-13 transcripts were 3.0-fold higher in the vehicle
treated animals (Figure 6E). Increased MMP expression levels
may have resulted from a positive feedback mechanism resulting
from efficient pharmacologic inhibition of MMP-activity, although
this would not explain downregulation of MMP-13 [22]. We
therefore performed an assay to investigate the ability of
Marimastat to inhibit gelatinase (MMP-2, MMP-9) and interstitial
collagenase (MMP-1) activities. Relative collagenase activity as
well as relative interstitial gelatinase activity in liver homogenates
supplemented with increasing concentrations of Marimastat
showed a dose-dependent inhibition of both these MMP-activities
(Figure 6F). These findings indicate efficient inhibition of
putatively fibrolytic MMPs by Marimastat, potentially leading to
increased fibrosis in the presence of continuous hepatic injury.
Broad spectrum MMP-inhibition with Marimastat using a
model of acute administration of a single dose of CCl4
predicts the evolution of the chronic CCl4 model
To further explore the anti-inflammatory and hepatoprotective
potential of pharmacologic broad-spectrum MMP and TACE
inhibition, C57Bl/6J mice were pretreated for 7 days with
Marimastat and subsequently challenged with a single dose of
CCl4. Analysis of liver sections at 12 h, 24 h, 48 h and 96 h time
points revealed that acute CCl4 intoxication resulted in severe
necroinflammatory injury around the central vein areas with a
peak at 24 h, regeneration and repair at 48 h characterized by
influx of macrophages and inflammatory lymphocytic infiltrates,
and impressive resolution of necrotic injury after 96 h (data not
shown). After 24 h, Marimastat pre-treatment attenuated necroin-
flammatory hepatic injury as determined by histology (Figure 7A),
and resulted in a 57% reduction in serum ALT levels (P#0.05,
Figure 7B). Since the peak of hepatic injury occurred after 24 h,
this time point was chosen as surrogate endpoint in subsequent
experiments.
Marimastat reduces necroinflammatory injury following a
single dose of CCl4 via a TNF-dependent pathway
Next, we studied if the anti-inflammatory and hepatoprotective
effects of Marimastat could be attributed to either an MMP- or a
TACE- dependent mechanism by using gene deleted animals.
MMP-9 is the major and most studied and abundant MMP in
inflammation [10,27], playing a critical role in fulminant TNF-
mediated hepatitis [28], mediating hepatic ischemia/reperfusion
injury [29] and being involved in liver regeneration [30]. Given
that Marimastat efficiently inhibits MMP-9 activity (Figure 6),
Mmp9 homozygous null mice (Mmp92/2) and their WT littermates
were subjected to a single dose of CCl4, or vehicle (mineral oil) to
investigate the involvement of a single MMP, rather than multiple
MMPs by pharmacologic broad-spectrum MMP-inhibition on
CCl4-induced hepatotoxicity. After 24 h liver sections from WT
animals and Mmp92/2 animals exhibited extensive centrilobular
necroinflammatory changes (Figure 7C). Serum ALT levels were
28,410 IU/L in WT animals compared to 28,100 IU/L in
Mmp92/2 animals (P=0.89; Figure 7D). Taken together, these
findings do not indicate that MMP-9 plays a significant role in the
acute phase of CCl4-induced hepatic injury.
The ability of Marimastat to inhibit TACE activity prompted us
to study the role of TNF-a signaling in CCl4-induced acute
hepatotoxicity. Since TACE is one of the major activators of TNF-
a, TACE-inhibition has been implicated as a promising anti-
inflammatory approach [17,24]. Because homozygous TACE
deletion is embryologically lethal [31], mice deficient in both
TNF-a receptors (TNF p552/2 p752/2) and their WT littermates
were used and subjected to either a single dose of CCl4 or mineral
oil, and sacrificed after 24 h to evaluate hepatic injury. Liver
sections from TNF p552/2 p752/2 mice revealed a marked
reduction of necroinflammatory injury, compared to WT controls
(Figure 7E). These findings were corroborated by a marked, 80%
reduction of serum ALT levels in TNF p552/2 p752/2 mice,
Figure 2. Marimastat treatment ameliorated hepatic injury and the inflammatory response following repeated carbon tetrachloride
(CCl4) administration. Marimastat treatment significantly reduced serum alkaline phosphatase levels (A), and resulted in a 14-fold decrease of
serum ALT (B), indicating decreased hepatic injury. Serum TNF-a receptor II (p75) levels as measured by ELISA decreased following Marimastat
treatment, suggesting successful inhibition of TNF-a converting enzyme (TACE) and an ameliorated inflammatory response. IL-6 serum levels as
measured by ELISA increased following Marimastat treatment, suggesting hepatoprotection and stimulated liver regeneration (D). Oil, non-fibrotic
control group; CCl4, fibrotic mice; VEH, vehicle treated control group; MAR, Marimastat treated experimental group; ALT, alanine aminotransferase;
TNF, tumor necrosis factor; IL, interleukin; *, P,0.05; ***, P,0.001 vs. vehicle alone. Data are expressed as means 6 standard error.
doi:10.1371/journal.pone.0011256.g002
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compared to CCl4-injected WT controls (4,581 IU/L and
22,660 IU/L, respectively, P#0.05; Figure 7F). This implicates
the involvement of TNF-signaling in CCl4-induced hepatic injury
and provides a mechanistic explanation for the hepatoprotective
effects of Marimastat in both acute, and chronic CCl4-induced
hepatic injury.
Discussion
The present study was aimed to determine the effects of the
broad spectrum MMP-inhibitor Marimastat on fibrosis formation
in a murine model of repeated, chronic CCl4-induced hepatic
injury. We demonstrate that pharmacologic pan-MMP inhibition
very efficiently decreased hepatic injury by amelioration of the
inflammatory response and by downregulation of pro-fibrogenic
mRNA expression, through interfering, at least in part, with TNF-
a activation and signaling. The detrimental effects of MMP-
inhibition on scar formation, however, were unexpected. We
initially hypothesized that inhibition of MMP activity would lead
to a further decrease in hepatic injury, rather than impacting on
collagen accumulation, resulting in decreased fibrosis formation.
Obviously, broad spectrum MMP-inhibition, as determined by
MMP transcript levels and activity assays, counterbalanced the
potential beneficial anti-fibrogenic and anti-inflammatory effects
by efficient inhibition of fibrolysis (Figure 8). This dissociation
between inflammation and liver injury on the one hand, and
fibrolysis on the other hand has to our knowledge not been
described previously and may provide novel insights in the dual
role of MMPs in fibrogenesis, and fibrolysis.
MMPs are secreted as zymogens and become activated by
cleavage of their propeptide [32,33]. Marimastat is a synthetic, low
molecular weight succinyl hydroxamate that inhibits MMPs via its
hydroxamate group that complexes the zinc ion needed in the
active site of MMPs [27]. Marimastat also inhibits TACE, with a
suggested benefit in diseases that involve both inflammation and
extracellular matrix remodeling [34]. Although MMPs were
traditionally viewed as molecules that were only involved in
degradation and turnover of the extracellular matrix, novel
insights overturned this dogma and revealed that MMPs modulate
the activities of a wide range of extracellular and intracellular
Figure 3. Marimastat altered the hepatic fibrosis-related gene expression profile by downregulation of multiple pro-fibrogenic
transcripts following repeated carbon tetrachloride (CCl4) administration. Hepatic procollagen a1(I) (A), b6 integrin (B), TGF-b1 (C), TGF-b2
(D), a-SMA (E) and TIMP-1 (F) expression as quantified by real-time RT-PCR in total liver RNA. Oil, non-fibrotic control group; CCl4, fibrotic mice; VEH,
vehicle treated control group; MAR, Marimastat treated experimental group; TGF, transforming growth factor; SMA, smooth muscle actin; TIMP, tissue
inhibitor of metalloproteinases; *, P,0.05; ***, P,0.001 vs. vehicle alone. Data are expressed as means6 standard error and in arbitrary units relative
to non-fibrotic vehicle treated control.
doi:10.1371/journal.pone.0011256.g003
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signaling pathways [22,23]. By regulating cell proliferation,
migration, adhesion, growth factor bioavailability, chemotaxis,
and cell signaling, MMPs are crucial for physiological and
pathophysiological processes such as inflammation, immunity,
angiogenesis, tumorigenesis, metastasis, and wound healing. As a
consequence, a broad spectrum MMP inhibitor such as Marima-
stat was expected to have both anti-inflammatory and potential
antifibrotic properties.
It has been generally accepted that changes in patterns of matrix
degradation are critical for fibrogenesis [35]; however, the role of
MMP activity in the liver during fibrogenesis is not yet fully
understood. In rodents, MMP-2, MMP-3, MMP-9, MMP-13,
MMP-14, as well as TIMP-1 and TIMP-2 are expressed in early
stages of HSC activation and have been implicated in fibrogenesis
as well as fibrolysis (reviewed in [20]). We confirmed that the
broad-spectrum MMP-inhibitor Marimastat efficiently inhibited
gelatinolytic and collagenolytic MMP, as well as TACE activities.
Among other pro-fibrogenic genes, hepatic transcript levels of a-
SMA were significantly decreased in the Marimastat treated
animals suggesting decreased activation of a subset of HSCs and
ameliorated fibrogenesis. This was confirmed by immunohisto-
chemical staining for a-SMA followed by quantification of positive
cell counts. It must be noted, however, that there exists
heterogeneity of gene expression in myofibroblastic cells during
fibrogenesis which reduces the usefulness of a-SMA as a marker
for collagen production [36]. MMPs such as MMP-8, MMP-9,
and MMP-13 possess the ability to degrade the extracellular
matrix by breakdown of fibrillar collagen type I [9,19,37]. MMP-9
may indirectly contribute to fibrolysis by accelerating HSC
apoptosis, whereas MMP-2 may rather drive hepatic stellate
Figure 4. Marimastat treatment increased hepatic fibrosis following repeated carbon tetrachloride (CCl4) administration. In mice
treated with Marimastat, the liver to body weight ratio (A), as well as the spleen to body weight ratio (B) were increased. Masson trichrome staining of
liver sections for collagen (blue; C) revealed bridging portal fibrosis. Livers from Marimastat treated animals showed occasional focal cirrhosis;
however, advanced fibrosis was predominant (C). Livers from Marimastat treated mice exhibited increased collagen deposition as determined
biochemically as relative hydroxyproline content and total hydroxyproline content in liver samples from two different lobes (D, E). Relative fibrotic
area was increased in livers from mice treated with Marimastat, as quantified using morphometric analysis of Sirius Red stained liver sections (F).
Oil, non-fibrotic control group; CCl4, fibrotic mice; VEH, vehicle treated control group; MAR, Marimastat treated experimental group; *, P,0.05;
**, P,0.01; ***, P,0.001 vs. vehicle alone. Data are expressed as means 6 standard error.
doi:10.1371/journal.pone.0011256.g004
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activation and unfavorable basement membrane remodeling
resulting in more fibrosis [20,38]. We demonstrated efficient
inhibition of gelatinolytic and collagenolytic MMP-activities which
as a whole has shifted the balance towards a net accumulation of
hepatic fibrosis.
TIMP-1 is the most relevant physiological MMP-inhibitor in
fibrotic diseases, including hepatotoxic and cholestatic injury,
whose expression is upregulated by various inflammatory
cytokines [32,33]. Antagonizing TIMP-1 using both neutralizing
antibodies and gene therapy, as well as indirect TIMP-1 mRNA
reduction by antagonizing inflammatory cytokines improved
experimental fibrosis in rodents [20]. In addition, transgenic mice
overexpressing human TIMP-1 developed more liver fibrosis
when subjected to chronic CCl4 administration [39], and
demonstrated attenuated spontaneous fibrosis resolution [40].
Reduced TIMP-1 levels may also accelerate hepatocyte prolifer-
ation following partial hepatectomy, illustrating its inhibitory role
in hepatocyte regeneration [41]. In our study, inflammation was
significantly decreased by TACE inhibition while downregulation
of TIMP-1 may have further improved hepatic regeneration, as
reflected by the marked decrease in serum levels of alkaline
phosphatase and ALT.
To further elucidate the hepatoprotective effects of broad
spectrum MMP-inhibition, we dosed Marimastat-pretreated
C57Bl/6J mice with a single injection of CCl4, to demonstrate
reduced centrilobular necrosis and a marked (57%) reduction in
Figure 5. Marimastat decreases hepatic stellate cell (HSC) activation, but increases recruitment of inflammatory cells. Chronic carbon
tetrachloride (CCl4) administration in animals treated with Marimastat resulted in a decreased activation of HSCs, as identified by alpha-smooth
muscle actin (a-SMA) staining (A). Quantification revealed that following chronic CCl4 administration, Marimastat treated animals had a 74% decrease
of activated HSCs, compared to controls (B). Liver sections from animals that were chronically challenged with CCl4 showed that resident T cells (CD3,
C,D) and macrophages (F4/80, E,F) counts increased up to 2-fold upon Marimastat treatment. Oil, non-fibrotic control group; CCl4, fibrotic mice; VEH,
vehicle treated control group; MAR, Marimastat treated experimental group; a-SMA, alpha-smooth muscle actin; *, P,0.05; **, P,0.01; ***, P,0.001
vs. vehicle alone. Data are expressed as means 6 standard error. Original magnification: 2006.
doi:10.1371/journal.pone.0011256.g005
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serum ALT levels corroborating the hepatoprotective effects of
Marimastat also in acute liver failure. These data are in line with a
previous report describing the use of a similar broad-spectrum
MMP-inhibitor (Batimastat; BB-94, British Biotech) in the
prevention of acute, fulminant hepatitis induced by TNF-a
combined with D-(+)-galactosamine [28]. In this study, mice
treated with BB-94 as well as mice deficient in Mmp2, Mmp3 or
Mmp9 had lower levels of apoptosis and necrosis of hepatocytes,
and better survival. Although TACE inhibitors are efficient in
protecting against lipopolysaccharide/D-(+)-galactosamine-in-
duced lethal hepatitis by inhibition of TNF-a release, inhibition
of TACE by BB-94 was deemed irrelevant in their model;
however, data was not shown [28]. The authors speculated that
the absence or presence of endogenous TNF-a does not influence
the outcome after TNF-a/D-(+)-galactosamine challenge [28].
Observations that soluble TNF-a receptor treatment improved
the outcome following acute CCl4-intoxication [42], and that
monoclonal antibodies against TNF-a improved experimental
CCl4-induced fibrosis [43] led us to explore the involvement of
TNF-a and TACE in CCl4-mediated hepatotoxicity. We show
that after a single dose of CCl4, animals pretreated with the broad-
spectrum MMP- and TACE-inhibitor Marimastat, as well as
animals deficient in both TNF-a receptors (p55 and p75) were
markedly protected, as demonstrated by attenuated necroinflam-
matory injury on histology and 5-fold lower serum ALT levels,
compared to their wild type controls. These findings indicate the
pivotal role of TNF-a signaling in CCl4 mediated hepatotoxicity.
A previous study failed to demonstrate a significantly ameliorated
response of TNF p552/2 p752/2 mice to acute CCl4 intoxication
[44], which is in contrast with our results. But these authors and
others found reduced fibrogenesis following repeated CCl4-
administration in animals lacking the TNF-a p55 receptor
supporting the involvement of TNF-signaling in CCl4-mediated
hepatotoxicity [44,45]. These data suggest that specific inhibition
of TACE may be an attractive approach to manipulate the
inflammatory cascade following a hepatic insult.
We also explored the possible involvement of MMP-9 in the
protection against acute CCl4-induced injury. A previous report
showed that acute CCl4-induced liver injury in rats increased both
active and latent MMP-9 to maximum levels at 24 h and
remained elevated 3 days following the injection, suggesting its
involvement in early hepatic injury [46]. We show that after a
Figure 6. Marimastat treatment downregulates matrix metalloproteinase (MMP) gene expression and MMP-activities. Following
repeated carbon tetrachloride (CCl4) administration, Marimastat did not affect hepatic transcript levels of MMP-2 (A), or MMP-3 (B) as quantified by
real-time RT-PCR. Hepatic MMP-8 (C) and MMP-9 (D) transcripts were significantly upregulated in livers from Marimastat treated animals, whereas
hepatic MMP-13 mRNA was significantly higher in the vehicle treated animals (E). Marimastat inhibits interstitial collagenolytic and gelatinolytic
activity in a dose-dependent matter (F). Relative gelatinase and interstitial collagenase activities after 4 hours in liver homogenates supplemented
with increasing concentrations of Marimastat, as determined by degradation of DQ-gelatin and collagen (black and grey squares, respectively). Oil,
non-fibrotic control group; CCl4, fibrotic mice; VEH, vehicle treated control group; MAR, Marimastat treated experimental group; TNF, tumor necrosis
factor; MMP, matrix metalloproteinase; *, P,0.05; **, P,0.01; ***, P,0.001 vs. vehicle alone. Data are expressed as means 6 standard error and in
arbitrary units.
doi:10.1371/journal.pone.0011256.g006
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single dose of CCl4 animals deficient in Mmp9 exhibited similar
hepatic injury compared to their wild type controls, as assessed by
histology and serum ALT levels after 24 h. The interpretation of
results with MMP knockout mice, however, is difficult since the net
proteolytic activity of MMPs relies upon complex, direct
interactions between the different protease and protease inhibitor
families. In addition, adaptive upregulation of gelatinolytic/
collagenolytic activities can have occurred, which would necessi-
tate a conditional knockout. Nevertheless, the almost identical
results of both Mmp92/2 animals and their wild type controls
largely rules out a major role of MMP-9 in the protection against
acute CCl4 intoxication.
More recently, another paper described attenuation of liver
injury following treatment with the MMP-inhibitor CTS-1027
(Conatus Pharmaceuticals, San Diego, CA, USA)[47]. Using the
bile duct ligation model, a decrease in hepatocyte apoptosis and a
reduction in markers for HSC activation and fibrogenesis was
demonstrated, which is in line with our results that Marimastat
attenuated hepatic inflammation and necrosis coupled with
downregulation of genes related to fibrogenesis. CTS-1027 is
Figure 7. Marimastat reduces necroinflammatory injury following a single dose of carbon tetrachloride (CCl4) via a TNF-dependent
pathway. Liver sections from Marimastat-treated animals that had been administered a single dose of CCl4 revealed decreased necroinflammatory
injury after 24 h (A). Marimastat treatment resulted in a 57% decrease of serum ALT levels (B). Liver sections from Mmp92/2 and wild type (Mmp9+/
+) animals that were challenged with a single dose of CCl4 showed comparable, extensive necroinflammatory changes around the central veins after
24 h (C). Serum ALT levels of Mmp92/2 animals were similar to those of wild type controls (D). 24 h after a single dose of CCl4, liver sections from
wild type (TNF p55+/+ p75+/+) animals revealed extensive necrosis and inflammation around the central veins, whereas TNF p552/2 p752/2
animals showed markedly reduced hepatic injury (E). Serum ALT levels in TNF p552/2 p752/2 animals were 5-fold lower compared to wild type
controls, corroborating the findings on histology and indicating decreased hepatic injury in animals lacking both TNF-receptors (F). Oil, non-fibrotic
control group; CCl4, fibrotic mice; VEH, vehicle treated control group; MAR, Marimastat treated experimental group; +/+, wild type controls; 2/2,
knock out animals; ALT, alanine aminotransferase; TNF, tumor necrosis factor; **, P,0.01 vs. vehicle alone. Data are expressed as means 6 standard
error. Original magnification: 3006.
doi:10.1371/journal.pone.0011256.g007
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actually now being further evaluated as a potential drug in patients
with Hepatitis C Virus [48]; however, we believe that in light of
our results caution is warranted. Although it was demonstrated
that two weeks of treatment with CTS-1027 resulted in
attenuation of collagen deposition in the bile duct ligation model,
we found that inhibition of MMP- and TACE-activity with
Marimastat during chronic CCl4 administration for 6 weeks
resulted in increased net fibrosis. It is well possible that two weeks
of MMP-inhibition may attenuate injury without aggravating
fibrosis, while longer-term treatment in the presence of ongoing
liver injury may shut down matrix degradation, eventually leading
to impaired fibrolysis. Although we cannot extrapolate our results
with Marimastat to all MMP inhibitors and potential off-target
effects of Marimastat may have contributed to our findings, it is
likely that long-term use of all such inhibitors with anti-TACE
activity will have similar divergent effects on liver injury and
fibrosis.
Clinically, Marimastat has been used in multiple oncologic
clinical trials up to phase III; however, its overall therapeutic
benefit was limited and the trials were halted [49–51]. The most
consistently reported side effect was musculoskeletal pain, likely
due to inhibition of adaptive ECM remodeling; however,
spontaneous fibrosis formation has never been reported. This
suggests that in the absence of chronic hepatic injury such as
hepatitis, or non-alcoholic steatohepatitis, broad-spectrum MMP-
inhibition is unlikely to be harmful to the liver. This may also
apply to other MMP-inhibitors such as the commonly prescribed
antibiotic doxycycline [52,53]. Nonetheless, we believe that
caution is warranted when patients with chronic, active liver
diseases receive MMP-inhibitors, since inhibition of fibrolytic
MMPs will likely accelerate hepatic fibrogenesis formation.
In conclusion, we demonstrate that broad-spectrum MMP- and
TACE-activity inhibition with Marimastat during chronic CCl4
administration resulted in significantly attenuated hepatic inflam-
mation and necrosis coupled with downregulation of genes related
to fibrogenesis, but resulted in increased liver fibrosis. Inhibition of
MMPs and collagen degradation by Marimastat, however,
counterbalanced the beneficial anti-inflammatory effect, resulting
in a positive balance of collagen deposition. Since effective
inhibition of fibrolytic activity by MMPs accelerates fibrosis
progression, our data suggests a note of caution for the use of
broad-spectrum MMP inhibitors in patients with chronic, ongoing
liver diseases, or for the treatment of liver fibrosis itself. Specific
inhibition of TACE, however, may still be an attractive approach
to manipulate the inflammatory cascade following a hepatic insult.
Methods
Ethics statement
Animal protocols complied with the National Institutes of
Health Animal Research Advisory Committee guidelines and were
approved by the Children’s Hospital Boston Animal Care and Use
Committee (protocol no. A06-08-065R).
Animals
Male 6-week-old C57BL6/J mice (Jackson Laboratories, Bar
Harbor, ME) were housed five per cage on paper chip bedding in
a barrier room with regulated temperature (21uC61.6uC),
humidity (45%610%), and an alternating 12-hour light and dark
cycle. The animals had free access to water and standard
American Institute of Nutrition (AIN) 93 M (TD.94048; Harlan
Teklad, Madison, WI) purified rodent diet throughout the study.
Animal experiments
After one week of acclimation, 40 C57BL6/J mice were
randomized into 4 groups (10 mice each). The first week, two
groups received 100 mg/kg of Marimastat (BB-2516, British
Biotech, UK) in 0.45% methylcellulose (Sigma-Aldrich, St. Louis,
MO) vehicle twice daily via orogastric gavage (MAR), and two
groups received vehicle alone (VEH). These treatments were
continued until study completion. Marimastat efficiently inhibits
MMP-2, MMP-3, MMP-7, MMP-9, MMP-13 and TACE activity,
with IC50s in the nM range [26,54]. After one week of treatment
with either Marimastat or vehicle, animals received three
intragastric doses via oral gavage (Monday, Wednesday and
Friday) of CCl4 (anhydrous, $99.5%, Sigma-Aldrich, St. Louis,
MO) dissolved in mineral oil (Sigma-Aldrich, St. Louis, MO) or
vehicle alone each week for another six weeks. The initial dose was
0.875 mL/kg, followed by 8 doses of 1.75 mL/kg and 9 doses of
2.5 mL/kg, respectively. At the end of the seven week treatment
period and three days after the last dose of CCl4, animals were
sacrificed to evaluate hepatic fibrosis and related parameters
(Figure 9A).
In separate experiments, the effect of MMP inhibition on acute
liver injury was studied in 64 C57BL6/J mice after orogastric
administration of a single dose of 1.5 mL/kg CCl4. Starting one
week prior to the hepatotoxic challenge, 32 mice received
100 mg/kg of Marimastat twice daily via orogastric gavage
(MAR), and 32 mice received vehicle alone (VEH). Treatment
was continued until sacrifice. Animals were sacrificed 12 h, 24 h,
48 h and 96 h after CCl4 administration (n=8 per treatment and
time point) to evaluate hepatic injury (Figure 9B). Since the peak
of hepatic injury occurred after 24 h, this time point was chosen as
surrogate endpoint in subsequent experiments.
The contribution of MMP and TACE-dependent pathways was
studied using mice deficient in MMP-9, as well as mice deficient in
both TNF-a receptors. Thirty mice homozygous null for theMmp9
Figure 8. Broad-spectrum matrix metalloproteinase (MMP)-
inhibition results in increased hepatic fibrosis following
chronic hepatic injury. In the absence of liver injury a physiological
balance exists between extracellular matrix synthesis and its degrada-
tion (A). Chronic hepatic injury causes excessive synthesis of
extracellular matrix proteins including collagen, which prevails over
their enzymatic degradation resulting in liver fibrosis (B). Despite a
significant attenuation of fibrogenesis and inflammation, efficient
inhibition of fibrolytic matrix metalloproteinases by a broad spectrum
MMP-inhibitor has profound effects on collagen degradation, tilting the
balance towards net extracellular matrix deposition and scar tissue
formation (C).
doi:10.1371/journal.pone.0011256.g008
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gene (B6.FVB(Cg)-Mmp9tm1Tvu/J mice; Jackson Laboratories, Bar
Harbor, ME) and their wild type (WT) littermates, and 30 mice
homozygous for both TNF-a receptor I (Tnfrsf1atm1Imx; p55) and
TNF-a receptor II (Tnfrsf1btm1Imx; p75) null mutations (B6;129S-
Tnfrsf1atm1Imx Tnfrsf1btm1Imx/J; Jackson Laboratories, Bar Harbor,
ME) and their WT littermates were subjected to either a single
dose of 1.5 mL/kg CCl4 via orogastric gavage, or mineral oil
(Figures 9C, D). Animals were sacrificed after 24 h to evaluate
hepatic injury.
Sample collection and serum biochemistry
Animals in all groups were euthanized, and pieces of their livers
fixed in 10% formalin for histology or immediately frozen and
stored for RNA extraction and hydroxyproline measurements.
Blood was collected via retro-orbital sinus puncture and plasma
was obtained via centrifugation. Serum was frozen at -80uC for
analysis of alanine aminotransferase (ALT) and alkaline phospha-
tase (AP) activities at the Clinical Laboratory of Children’s
Hospital Boston. Serum levels of IL-6 and the soluble TNF-a
receptor II (p75) were determined using a commercial ELISA kit
(Quantikine, R&D Systems, Minneapolis, MN). Optical density
was read at 450 nm and analyzed with Softmax PRO Software
(Molecular Devices, Sunnyvale, CA).
Histology
Paraffin-embedded sections from the frontal lobes of the liver
were stained by hematoxylin and eosin (H&E) to examine cellular
architecture and lipid accumulation. A pathologist (VN) blinded to
the treatment groups conducted a histological analysis of the liver
sections [55]. Lobular inflammation was quantified by assessing
the number of inflammatory foci per microscopic field. Five fields
were checked at 2006magnification as follows: 0 (absent), 1 (,2
foci), 2 (2–4 foci), and 3 (.4 foci). Steatosis was scored by the
percentage (%) of liver cells containing fat: 0 (,5%), 1 (5–33%), 2
(.33–66%) and 3 (.66%). Necrosis was scored as 0 (absent) or 1
(pericentral area occupied by necrosis).Masson trichrome (MT)
and Sirius Red stains of paraffin-embedded sections were used to
qualitatively assess collagen architecture and extent of fibrosis.
Morphometric analysis for fibrosis quantification was performed
using ten random high power fields (HPF) per animal at 2006
magnification. These images were quantified using NIH ImageJ
software (http://rsb.info.nih.gov/ij/).
Immunohistochemistry
Immunohistochemistry was performed using 4 mm thick
formalin-fixed, paraffin-embedded tissue sections. Briefly, slides
were soaked in xylene, passed through graded alcohols and put in
distilled water. Slides were then pre-treated with 1.0-mM EDTA,
pH 8.0 (Zymed, South San Francisco, CA) for anti-CD3 or
Citrate buffer for anti-alpha smooth muscle actin (a-SMA) in a
steam pressure cooker (Decloaking Chamber, BioCare Medical,
Walnut Creek, CA) as per manufacturer’s instructions followed by
washing in distilled water. All further steps were performed at
room temperature in a hydrated chamber. Slides were pre-treated
with Peroxidase Block (DAKO USA, Carpinteria, CA) for 5
minutes to quench endogenous peroxidase activity. For CD3,
polyclonal rabbit anti-murine CD3 antibody (Cell Marque,
Rocklin, CA. Cat #CMC363) was applied 1:1500, and for a-
SMA, rabbit anti-murine a-SMA (Abcam, Cambridge, MA, Cat
#ab5694) was applied 1:200 in diluent (DAKO) for 1 hour. Slides
were washed in 50-mM Tris-Cl, pH 7.4, and antigens detected
with anti-rabbit Envision+ kit (DAKO) as per manufacturer’s
instructions. After further washing, immunoperoxidase staining
was developed using a DAB chromogen (DAKO) and counter-
stained with hematoxylin. For F4/80 staining, slides were
incubated with proteinase K applied 1:5 in DAKO diluent for
10 minutes and then washed in 50-mM Tris-Cl, pH 7.4, followed
by incubation with rat F4/80 antibody (Serotec, Raleigh, NC,
cat#MCA497GA) applied 1:10,000 in DAKO diluent for 1 hour.
Slides were then washed and incubated with rabbit anti-rat
secondary (DAKO) diluted 1:750 for 30 minutes, washed, and
detected with anti-rabbit Envision+ kit (DAKO) as described
above. For quantification purposes, positive cells were counted in
ten random HPF per animal at 2006magnification and expressed
as mean positive cells/10 HPF.
Liver hydroxyproline determination
Hepatic collagen content was quantified biochemically by
determining liver hydroxyproline using an established method
with minor modifications [56–58]. Briefly, snap-frozen liver tissue
from two different lobes (50–60 mg each) was hydrolyzed at 110uC
for 16 h in 5 mL 6N HCl. The hydrolysate was filtered, 50-mL
aliquots were evaporated under vacuum, and the sediment was
dissolved in 1.2 mL of 50% isopropanol and incubated with
0.2 mL of 0.84% chloramine-T in 42 mmol/L sodium acetate,
Figure 9. Design of the studies. Two groups of C57Bl/6J mice were randomized to two subgroups to receive either Marimastat or methylcellulose
vehicle twice daily (A). Liver fibrosis was induced by repeated carbon tetrachloride (CCl4) administration for 6 weeks in one group of animals, whereas
a second group of control animals received the mineral oil vehicle alone (A). The protective effects of Marimastat were further evaluated in a model of
acute CCl4-induced hepatotoxicity (B). C57Bl/6J mice received either Marimastat or methylcellulose vehicle twice daily for 1 week, after which they
were subjected to a single dose of CCl4 or mineral oil as control (B). The mechanism was further elucidated by subjecting Mmp92/2 mice and their
wild type (WT) littermates (C), or TNF p552/2p752/2 mice and their WT littermates (D) to either a single dose of CCl4, or mineral oil. In all acute
CCl4-experiments, animals were sacrificed after 24 hours. Oil, non-fibrotic control group; CCl4, fibrotic mice; VEH, vehicle treated control group; MAR,
Marimastat treated experimental group; WT, wild type.
doi:10.1371/journal.pone.0011256.g009
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2.6 mmol/L citric acid, and 39.5% (vol/vol) isopropanol (pH 6.0),
followed by incubation for 10 minutes at room temperature. Next,
0.248 g p-dimethylaminobenzaldehyde, dissolved in 0.27 mL of
60% perchloric acid, and 0.73 mL isopropanol were added and
incubated at 50uC for 90 minutes. Relative hydroxyproline (mg/g
liver) was then quantified photometrically at 558 nm and total
hydroxyproline (mg/whole liver) was calculated based on
individual liver weights and the corresponding relative hydroxy-
proline content from representative liver samples, as established
previously [57,58].
Quantitative Real-Time RT-PCR
200–300 mg snap-frozen liver tissue from two lobes was
homogenized; total RNA was extracted using Tri Reagent
(Molecular Research Center, Cincinnati, OH) and reverse
transcribed as described [58,59]. Relative transcript levels were
quantified by real-time RT-PCR on a LightCycler 1.5 instrument
(Roche, Mannheim, Germany) using the TaqMan methodology as
described in detail [57–59]. TaqMan probes (dual-labeled with 59-
FAM and 39-TAMRA) and primers were designed based on
published sequences (Table 1) using the Primer Express software
(Perkin Elmer, Wellesley, USA), synthesized at MWG Biotech AG
(Ebersberg, Germany), and are published elsewhere [57,59]. The
housekeeping gene beta-2 microglobulin (b2MG) was amplified in
parallel reactions for normalization.
Gelatinase and Interstitial Collagenase Activity Assays
Determination of gelatinase and interstitial collagenase activity
was performed as described previously with assays based on
degradation of DQ-gelatin and DQ-collagen type I, respectively
(Molecular Probes Inc., Eugene, OR) [58,59]. DQ-substrates are
heavily labeled with FITC which quenches their fluorescence, but
fluorescent peptides are generated upon proteolytic cleavage.
20 mL of 10% liver homogenates prepared as described previous-
ly[57] were diluted in a total volume of 200 mL of MMP-activity
buffer (50 mM Tris-HCl, 150 mM NaCl, 5 mM CaCl2, 0.025%
Brij 35TM, pH 7.5, supplemented with EDTA-free protease
inhibitor cocktail (CompleteTM, Roche Applied Science, Mann-
heim, Germany)) and incubated with DQ-substrates (25 mg/mL)
and increasing doses of Marimastat dissolved in H2O at room
temperature for 1–20 h in 96-well plates in triplicates. Fluores-
cence was measured using the Wallac Victor2 Multilabel Counter
(PerkinElmer, Inc., Waltham, MA); with excitation at 485 nm,
and emission at 535 nm. Human recombinant activated MMP-1
(collagenase) and MMP-2 (gelatinase) were used as positive
controls. Since all procedures including extraction were performed
in the presence of protease inhibitors to prevent ex vivo MMP
activation, data obtained represent the net endogenous gelatino-
lytic and collagenolytic activities.
Statistical analysis
Data are expressed as means 6 standard error of the mean
(SEM). Data sets involving more than two groups were assessed by
analysis of variance (ANOVA). Differences between two groups
were assessed using the unpaired two-tailed Student’s t test, or if
nonparametric, by using the Mann-Whitney U test. P#0.05 was
considered statistically significant. All data were collected in a
computerized Microsoft Excel database (Microsoft Inc., Red-
mond, WA). The analysis was performed with SPSS version 16.0
(SPSS Inc., Chicago, IL) statistical software, and figures were
created using GraphPad Prism version 5.0 (GraphPad Software
Inc., La Jolla, CA) software.
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